• Target：
• CD41

• Fields：
• >>Rap1 signaling pathway;>>PI3K-Akt signaling pathway;>>Focal adhesion;>>ECM-receptor interaction;>>Platelet activation;>>Neutrophil extracellular trap formation;>>Hematopoietic cell lineage;>>Regulation of actin cytoskeleton;>>Human papillomavirus infection;>>Pathways in cancer;>>Small cell lung cancer;>>Hypertrophic cardiomyopathy;>>Arrhythmogenic right ventricular cardiomyopathy;>>Dilated cardiomyopathy;>>Fluid shear stress and atherosclerosis

• Gene Name：
• ITGA2B GP2B ITGAB

• Protein Name：
• ITGA2B (heavy chain, Cleaved-Leu32)

• Human Gene Id：
• 3674

• Human Swiss Prot No：
• P08514

• Mouse Gene Id：
• 16399

• Mouse Swiss Prot No：
• Q9QUM0

• Immunogen：
• Synthesized peptide derived from human ITGA2B (heavy chain, Cleaved-Leu32)

• Specificity：
• This antibody detects endogenous levels of Human ITGA2B (heavy chain, Cleaved-Leu32, protein was cleaved amino acid sequence between 31-32 )

• Formulation：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Source：
• Polyclonal, Rabbit,IgG

• Dilution：
• WB 1:500-2000;IHC 1:50-300

• Purification：
• The antibody was affinity-purified from rabbit serum by affinity-chromatography using specific immunogen.

• Concentration：
• 1 mg/ml

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• Integrin alpha-IIb (GPalpha IIb;GPIIb;Platelet membrane glycoprotein IIb;CD antigen CD41) [Cleaved into: Integrin alpha-IIb heavy chain;Integrin alpha-IIb light chain, form 1;Integrin alpha-IIb light chain, form 2]

• Observed Band(KD)：
• 95 110kD

• Background：
• This gene encodes a member of the integrin alpha chain family of proteins. The encoded preproprotein is proteolytically processed to generate light and heavy chains that associate through disulfide linkages to form a subunit of the alpha-IIb/beta-3 integrin cell adhesion receptor. This receptor plays a crucial role in the blood coagulation system, by mediating platelet aggregation. Mutations in this gene are associated with platelet-type bleeding disorders, which are characterized by a failure of platelet aggregation, including Glanzmann thrombasthenia. [provided by RefSeq, Jan 2016],

• Function：
• disease:Defects in ITGA2B are a cause of Glanzmann thrombasthenia (GT) [MIM:273800]; also known as thrombasthenia of Glanzmann and Naegeli. This autosomal recessive disorder is the most common inherited disease of platelets. GT is characterized by mucocutaneous bleeding of mild-to-moderate severity and the inability of this integrin to recognize macromolecular or synthetic peptide ligands. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb/beta-3 complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the glycoprotein IIb/beta-3 complex at reduced levels (5-20% controls), have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The platelets of GT 'variants' have normal or near normal (60-100%) expression of dysfunctional receptors.,fun

• Subcellular Location：
• Membrane; Single-pass type I membrane protein.

• Expression：
• Isoform 1 and isoform 2 are expressed in platelets and megakaryocytes, but not in reticulocytes. Not detected in Jurkat, nor in U937 cell lines (PubMed:2351656). Isoform 3 is expressed in prostate adenocarcinoma, as well as in several erythroleukemia, prostate adenocarcinoma and melanoma cell lines, including PC-3, DU-145, HEL, WM983A, WM983B and WM35. Not detected in platelets, nor in normal prostate (at protein level) (PubMed:9809974).

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs